Exp Clin Endocrinol Diabetes 2004; 112(4): 201-207
DOI: 10.1055/s-2004-817934

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Weight Reduction by Sibutramine in Obese Subjects in Primary Care Medicine: The S. A. T. Study

H. Hauner1 , M. Meier1 , G. Wendland2 , T. Kurscheid2 , K. Lauterbach2 , S. A. T. Study Group1
  • 1German Diabetes Research Institute, Düsseldorf, Germany
  • 2Institute of Health Economics and Clinical Epidemiology, University of Köln, Germany
Further Information

Publication History

Received: September 20, 2002 First decision: November 24, 2002

Accepted: October 6, 2003

Publication Date:
04 May 2004 (online)


Background: Sibutramine is a selective serotonin and noradrenaline reuptake inhibitor that is known to reduce body weight. The efficacy of this drug in primary care medicine is currently unknown.

Objective: To study, in a primary healthcare setting, the effect of a standardized non-pharmacological treatment program and 15 mg sibutramine or placebo on long-term weight reduction in obese subjects with a body mass index ≥ 30 and < 40 kg/m².

Design: A multicentre, double-blind, placebo-controlled, randomized, parallel group comparison over 54 weeks of continuous therapy.

Setting: 33 general practitioners in Germany.

Subjects: 389 obese patients were recruited of whom 362 were randomized.

Measurements: Primary measure was weight reduction at week 54; others included reduction in BMI, waist circumference, waist-hip ratio, blood pressure and blood lipids.

Results: 348 obese subjects were analyzed using an intention-to-treat analysis. Mean weight loss in the sibutramine (S) group was 8.1 ± 8.2 kg vs. 5.1 ± 6.5 kg in the placebo (P) group (p < 0.001; Intent-to-treat analysis). More subjects lost more than 5 % and 10 % of initial weight with sibutramine than with placebo (5 %, S: 62.6 %, P: 41.4 %, p < 0.001; 10 %, S: 40.8, P: 19.0 %, p < 0.001). Weight loss was accompanied by an improvement in the lipid profile, in particular, an increase in HDL-cholesterol and a decrease in fasting triglycerides. In both groups, systolic and diastolic blood pressure decreased in those with moderate hypertension and remained unchanged in those with normal blood pressure at baseline. There was a modest increase in heart rate in S (1.9 beats/min) vs. P (- 0.9 beats/min) (p < 0.05).

Conclusions: Under primary care conditions, sibutramine 15 mg daily proved to be a safe and effective drug for additional weight loss in obese subjects undergoing a comprehensive weight reduction program.


  • 1 Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.  Am J Med. 1999;  106 179-184
  • 2 Birkenfeld A L, Schroeder C, Boschmann M, Tank J, Franke G, Luft F C, Biaggioni J, Sharma A M, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation.  Circulation. 2002;  106 2459-246
  • 3 Bray G A, Blackburn G L, Ferguson J M, Greenway F L, Jain A K, Mendel C M, Mendels J, Ryan D H, Schwartz S L, Scheinbaum M L, Seaton T B. Sibutramine produces dose-related weight loss.  Obes Res. 1999;  7 189-198
  • 4 Expert Panel on the Identification .Clinical Guidelines On the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The Evidence Report. Bethesda; National Institute of Health, National Heart, Lung and Blood Institute 1998
  • 5 Fleiss J L. The Design and Analysis of Clinical Experiments. Hoboken, New Jersey; John Wiley & Sons 1986
  • 6 Hanotin C, Thomas F, Jones S P, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.  Int J Obes Relat Metab Disord. 1998;  22 32-38
  • 7 Hansen D L, Toubro S, Stock M J, Macdonald I A, Astrup A. Thermogenic effects of sibutramine in humans.  Am J Clin Nutr. 1998;  68 1180-1186
  • 8 James W PT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris W H, van Gaal L F. for the STORM Study Group . Effect of sibutramine on weight maintenance after weight loss: a randomized trial.  Lancet. 2000;  356 2119-2125
  • 9 Lean M EJ. Sibutramine - a review of clinical efficacy.  Int J Obes Rel Metab Disord. 1997;  21 (Suppl 1) S30-S36
  • 10 National Task Force on the Prevention and Treatment of Obesity . Long-term pharmacotherapy in the management of obesity.  JAMA. 1996;  276 1907-1915
  • 11 Perri M G, Nezu A M. Preventing relapse following treatment for obesity. Stunkard AJ, Wadden TA Obesity: Theory and Therapy. New York; Raven Press 1993: 288-299
  • 12 Pi-Sunyer F X. Medical hazards of obesity.  Ann Intern Med. 1993;  110 655-660
  • 13 Report of a WHO consultation on obesity. Obesity - Preventing and Managing the Global Epidemic. WHO Geneva; WHO Technical Report Series 894 2000
  • 14 Rolls B J, Shide D J, Thorwart M L, Ulbrecht J S. Sibutramine reduces food intake in non-dieting women with obesity.  Obes Res. 1998;  6 1-11
  • 15 Royal College of Physicians .Overweight and Obese Patients. Principles of Management with Particular Reference to the Use of Drugs. London; 1997
  • 16 Stock M J. Sibutramine: a review of the pharmacology of a novel anti-obesity drug.  Int J Obes Relat Metab Disord. 1997;  2 (Suppl 2) S25-S29
  • 17 Walsh K M, Leen E, Lean M E. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females.  Int J Obes Rel Metab Disord. 1999;  23 1009-1015
  • 18 Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial.  JAMA. 2001;  286 1331-1339

M. D. Hans Hauner

Else-Kröner-Fresenius-Zentrum für Ernährungsmedizin der TU München
Klinikum Rechts der Isar

Ismaninger Straße 22

81675 München


Phone: + 498941406770

Fax: + 49 89 41 40 67 72

Email: hauner@wzw.tum.de